Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982

Online
ISSN
1437-4331
See all formats and pricing
In This Section
Volume 54, Issue 5 (May 2016)

Issues

Effective quality management practices in routine clinical next-generation sequencing

Francine B. de Abreu
  • Department of Pathology, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH, USA
/ Jason D. Peterson
  • Department of Pathology, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH, USA
/ Christopher I. Amos
  • Center for Genomic Medicine and Department of Community and Family Medicine, Giesel School of Medicine at Dartmouth, Hanover, NH, USA
/ Wendy A. Wells
  • Department of Pathology, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH, USA
/ Gregory J. Tsongalis
  • Corresponding author
  • Department of Pathology, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH, USA
  • Email:
Published Online: 2016-02-12 | DOI: https://doi.org/10.1515/cclm-2015-1190

Abstract

Background:

Molecular technologies have allowed laboratories to detect and establish the profiles of human cancers by identifying a variety of somatic variants. In order to improve personalized patient care, we have established a next-generation sequencing (NGS) test to screen for somatic variants in primary or advanced cancers. In this study, we describe the laboratory quality management program for NGS testing, and also provide an overview of the somatic variants identified in over 1000 patient samples as well as their implications in clinical practice.

Methods:

Over the past one-and-a-half years, our laboratory received a total of 1028 formalin-fixed, paraffin-embedded (FFPE) tumor tissues, which consisted of non-small-cell lung carcinomas (NSCLCs), colon adenocarcinomas, glioma/glioblastomas, melanomas, breast carcinomas, and other tumor types. During this time period, we implemented a series of quality control (QC) checks that included (1) pre-DNA extraction, (2) DNA quantification, (3) DNA quality, (4) library quantification, (5) post-emulsification PCR, and (6) post-sequencing metrics. At least 10 ng of genomic DNA (gDNA) were used to prepare barcoded libraries using the AmpliSeq CHPv2. Samples were multiplexed and sequenced on Ion Torrent 318 chips using the Ion PGM System. Variants were identified using the Variant Caller Plugin, and annotation and functional predictions were performed using the Golden Helix SVS.

Results:

A total of 1005 samples passed QC1–3, and following additional library preparation QC checkpoints, 877 samples were sequenced. Samples were classified into two categories: wild-type (127) and positive for somatic variants (750). Somatic variants were classified into clinically actionable (60%) and non-actionable (40%).

Conclusions:

The use of NGS in routine clinical laboratory practice allowed for the detection of tumor profiles that are essential for the selection of targeted therapies and identification of applicable clinical trials, contributing to the improvement of personalized patient care in oncology.

Keywords: massively parallel sequencing; next-generation sequencing; solid tumor; somatic variant

References

  • 1.

    Ross JS, Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol 2011;136:527–39.

  • 2.

    Yu B, O’Toole SA, Trent RJ. Somatic DNA mutation analysis in targeted therapy of solid tumours. Transl Pediatr 2015;4:125–38.

  • 3.

    Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med 2013;15:733–47.

  • 4.

    Aziz N, Zhao Q, Bry L, Driscoll DK, Funke B, Gibson JS, et al. College of American pathologists’ laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med 2015;139:481–93.

  • 5.

    Tsongalis GJ, Peterson JD, de Abreu FB, Tunkey CD, Gallagher TL, Strausbaugh LD, et al. Routine use of the ion torrent AmpliSeqTM Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med 2013;13:1–8.

  • 6.

    Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol 2014;27:314–27.

  • 7.

    Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014;20:682–8.

  • 8.

    Gailey MP, Stence AA, Jensen CS, Ma D. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue. Cancer Cytopathol 2015;123:30–9.

  • 9.

    Dumur CI. Available resources and challenges for the clinical annotation of somatic variations. Cancer Cytopathol 2014;122:730–6.

  • 10.

    Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen – the clinical genome resource. N Engl J Med 2015;372:2235–42.

  • 11.

    Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 2014;19:616–22.

  • 12.

    Janne PA, Smith I, McWalter G, Mann J, Doughrty B, Walker J, et al. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. Br J Cancer 2015;113:199–203.

  • 13.

    Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, et al. On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol Cancer Ther 2015;14:1488–94.

  • 14.

    Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, et al. Molecular tumor board: the University of California San Diego moores cancer center experience. Oncologist 2014;19:631–6.

  • 15.

    Tafe LJ, Gorlov I, de Abreu FB, Lefferts JA, Liu X, Pettus JR, et al. Implementation of a Molecular tumor board: the impact on treatment decisions for the first 35 patients evaluated at Dartmouth-Hitchcock Medical Center. Oncologist 2015;20:1011–8.

  • 16.

    Burrel RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338–45.

  • 17.

    Burrel RA, Swanton C. Tumor heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014;8:1095–111.

  • 18.

    Pribluda A, de la Cruz CC, Jackson EL. Intratumoral heterogeneity: from diversity comes resistance. Clin Cancer Res 2015;21:2916–22.

  • 19.

    Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implication of tumor heterogeneity. Clin Cancer Res 2015;21:1258–66.

  • 20.

    Swanton C. Cancer evolution: the final frontier of precision medicine? Ann Oncol 2014;25:549–51.

  • 21.

    Janku F. Tumor heterogeneity in the clinic: is it a real problem? Ther Adv Med Oncol 2014;6:43–51.

  • 22.

    Jorgensen JT. Clinical application of companion diagnostics. Trends Mol Med 2015;21:405–7.

  • 23.

    Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, et al. Clinical utility of patient derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol 2015;33:2472–80.

About the article

Corresponding author: Gregory J. Tsongalis, PhD, Department of Pathology, Dartmouth Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756, USA, Phone: +1-603-650-5498, E-mail:


Received: 2015-11-30

Accepted: 2016-01-14

Published Online: 2016-02-12

Published in Print: 2016-05-01


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2015-1190. Export Citation

Comments (0)

Please log in or register to comment.
Log in